SCHEMBL6323045

SCHEMBL6323045

CCOC(=O)c1noc(CCN)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.39
BMP1 P13497 2/20 0.39
KMT2A Q03164 4/20 0.39
LMNA P02545 5/20 0.38
MAPT P10636 4/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 3/20 0.38
MAPK1 P28482 3/20 0.38
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CACNA1F O60840 1/20 0.38
CACNA1D Q01668 1/20 0.38
CACNA1S Q13698 1/20 0.38
CACNA1C Q13936 1/20 0.38
GLA P06280 1/20 0.37
CYP1A2 P05177 3/20 0.37
CYP3A4 P08684 1/20 0.37
MAOA P21397 1/20 0.37
SLC26A6 Q9BXS9 3/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6330573 0.98 MMP2 (0.38) MMP2BMP1KMT2ALMNAMAPT
SCHEMBL4489619 0.87 KMT2A (0.40) MMP2BMP1KMT2AMAPTALDH1A1
Hydrochloric Acid SCHEMBL6328451 0.86 KMT2A (0.40) MMP2BMP1KMT2AMAPTALDH1A1
Hydrochloric Acid SCHEMBL4489615 0.86 KMT2A (0.40) MMP2BMP1KMT2AMAPTALDH1A1
SCHEMBL15932098 0.84 MMP2 (0.41) MMP2BMP1KMT2ALMNAMAPT
SCHEMBL3214456 0.81 KMT2A (0.43) MMP2BMP1KMT2AALDH1A1MEN1
SCHEMBL6623419 0.81 MAPK1 (0.44) MMP2BMP1KMT2ALMNAMAPT
SCHEMBL12002524 0.79 KMT2A (0.40) MMP2BMP1KMT2ALMNAMAPT
SCHEMBL29110021 0.79 KMT2A (0.40) MMP2BMP1KMT2AMAPTALDH1A1
SCHEMBL1934380 0.78 SLC26A6 (0.40) MMP2BMP1KMT2AALDH1A1SLC26A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
WO-2022094012-A1 MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-05-05 WO disclosed
US-6951946-B2 Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates LEXICON PHARMACEUTICALS, INC. (US) 2005-10-04 US disclosed
US-20050154211-A1 Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates KOLB HARTMUTH C (US) 2005-07-14 US disclosed
US-20040019215-A1 Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates LEXICON PHARMACEUTICALS, INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS MMP2 4016/4885BMP1 4561/4885KMT2A 4371/4885
US-20050154211-A1 Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates OXA1L, ODC1, CYP4B1 MMP2 3190/4885BMP1 1072/4885KMT2A 3220/4885
US-20040019215-A1 Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates OXA1L, ODC1, CYP4B1 MMP2 3190/4885BMP1 1072/4885KMT2A 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.